Cadrenal Therapeutics, Inc. CVKD
Set alert
0.99 USD +0.04 +4.41%
At close · Oct 30
0.99 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
0.94 Day range 1.00
0.872 52-week range 13.66
- YTD
- -85.47%
- 1 year
- -92.38%
- Open
- 0.94
- Prev close
- 0.9434
- Mkt cap
- 3.05M
- Vol
- 80.68K
- Avg vol
- 468.23K
- EPS
- -4.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.94
- High
- 1.00
- Forward P/E
- -3.02
- Beta
- 0.00
- Short ratio
- 1.17
- Inst. own
- 4.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 14.77
- 200-d avg
- 9.61
- 1y target
- 35.67
2Y chart
Events in this range
- Nov 7, 2024Earnings: -2.18; estimate -1.83; surprise -19.13%
- Nov 11, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (67)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| RSI: Oversold | Sep 2, 2026 | 2 months ago |
| RSI: Oversold | Aug 17, 2026 | 2 months ago |
| RSI: Oversold | Aug 6, 2026 | 2 months ago |
| RSI: Oversold | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 27, 2026 | 3 months ago |
| RSI: Oversold | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| RSI: Oversold | Jun 24, 2026 | 4 months ago |
| RSI: Oversold | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 6, 2026 | 5 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| RSI: Oversold | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 13, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| RSI: Oversold | Feb 17, 2026 | 8 months ago |
| RSI: Oversold | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| SMA: Bearish | Dec 16, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| RSI: Oversold | Nov 25, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 6, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 5, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 14, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 7, 2025 | 1 year ago |
| RSI: Oversold | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| RSI: Oversold | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 4, 2025 | 1 year ago |
| MACD: Sell Signal | May 27, 2025 | 1 year ago |
| MACD: Buy Signal | May 20, 2025 | 1 year ago |
| RSI: Oversold | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 8, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| SMA: Bullish | Mar 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 6, 2025 | 1 year ago |
Key statistics
- Market cap
- 23.65M
- Enterprise value
- 13.49M
- Trailing P/E
- 0.00
- Forward P/E
- -3.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.61
- EPS (TTM)
- -6.73
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -3.67M
- Total cash
- 4.36M
- Total debt
- 2.23K
- Return on equity
- -125.15%
- Shares outstanding
- 1.66M
- Short % of float
- 6.80%
- 50-day average
- 14.77
- 200-day average
- 9.61
Analyst view
Consensus: none
Price target (mean) 35.67 +3521.0% upside
Now 0.985
- Target (low)
- 30.00
- Target (mean)
- 35.67
- Target (high)
- 45.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -1.87.
Financials — quick view
CVKD Revenue — quarterly 0
CVKD Net income — quarterly -3.32M
CVKD EPS — quarterly -1.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.83 | -2.18 | -0.35 | -19.13% |
| Aug 7, 2024 | Jun 1, 2024 | -19.04 | -2.25 | +16.79 | +88.18% |
| Aug 7, 2024 | Jun 1, 2024 | -19.04 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.05 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.05 | -1.50 | -0.45 | -42.86% |
| Mar 11, 2024 | Dec 1, 2023 | -1.35 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 18, 2023 | Noble Capital Markets | init | — | Outperform |
| Nov 20, 2023 | HC Wainwright & Co. | init | — | Buy |
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cadrenal.com
News
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
- Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
- Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Monday's Intraday Session
Your note
Sign in to keep a note on CVKD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MURPHY JOHN RAYMOND | Director | Purchase | Oct 4, 2023 | 614,792 |
| PHAM QUANG X | Chief Executive Officer | Stock Gift | Apr 9, 2024 | 6,275,000 |
| SZOT MATTHEW K | Chief Financial Officer | Stock Award(Grant) | Jan 23, 2023 | 500,000 |
| WILSON GLYNN | Director | Conversion of Exercise of derivative security | Jan 23, 2023 | 50,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Royal Bank of Canada | 0.00% | 25 | 356 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 5 | 71 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.19% | 3,216 | 45.86K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 1,109 | 15.81K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 923 | 13.16K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 60 | 855 | Sep 29, 2024 |